Please assess the completion status of the following clinical trial:

Trial Title: A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Stage IIIB (with effusion) or Stage IV NSCLC any histology~* No prior chemotherapy~* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1~* Greater than or equal to 18 years of age~* Life expectancy at least 12 weeks~* Adequate bone marrow, liver and renal function~Exclusion Criteria:~* Prior systemic anti cancer therapy~* Known brain metastasis. Patients with neurological symptoms should undergo at computed tomography (CT) scan/magnetic resonance imaging (MRI) of the brain to exclude brain metastasis~* Pulmonary hemorrhage/bleeding event \> Common Terminology Criteria for Adverse Events (CTCAE) Grade 2 within 4 weeks of first dose of study drug~* Thrombotic or embolic events including Transient ischemic attack (TIA) within the past 6 months~* Uncontrolled hypertension~* Any other hemorrhage/bleeding event \> CTCAE Grade 3 within 4 weeks of first dose of study drug~* Major surgery within 4 weeks~* Evidence or history of bleeding diathesis or coagulopathy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sorafenib + C/P (Type: EXPERIMENTAL): Chemotherapy Phase up to 6 cycles: Sorafenib (Nexavar, BAY43-9006), \[400 mg orally, twice daily\] on Study Days 2-19 and paclitaxel (P) (200 mg/m2, intravenous (IV)) and carboplatin (C) (area under the curve (AUC) =6 mg/ml\*min-1, IV) on Study Day 1. The cycle duration 21 days. Maintenance Phase: Sorafenib 400 mg orally twice daily was administered on Days 1-21 of each 21-day cycle.
- Placebo + C/P (Type: ACTIVE_COMPARATOR): Chemotherapy Phase up to 6 cycles: Sorafenib Placebo (2 tablets orally twice daily\] on Study Days 2-19 and paclitaxel (200 mg/m2, intravenous (IV)) and carboplatin (area under the curve (AUC) =6 mg/ml\*min-1, IV) on Study Day 1. The cycle duration 21 days. Maintenance Phase: Sorafenib Placebo 2 tablets orally twice daily was administered on Days 1-21 of each 21-day cycle.

Based on this trial design, predict the completion outcome and termination type (if applicable).